Literature DB >> 17940536

The clinical relevance of percentage improvements on the PANSS score.

W Wolfgang Fleischhacker, Georg Kemmler.   

Abstract

Mesh：

Year:  2007        PMID： 17940536     DOI： 10.1038/sj.npp.1301391

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  9 in total

1.  Effectiveness as an outcome measure for treatment trials in psychiatry.

Authors:  W Wolfgang Fleischhacker; Guy M Goodwin
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

Review 2.  Progress in defining optimal treatment outcome in schizophrenia.

Authors:  Gary Remington; George Foussias; Ofer Agid
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

3.  Should the PANSS be rescaled?

Authors:  Michael Obermeier; Andreas Mayr; Rebecca Schennach-Wolff; Florian Seemüller; Hans-Jürgen Möller; Michael Riedel
Journal:  Schizophr Bull       Date:  2009-11-04       Impact factor: 9.306

4.  Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis.

Authors:  Kenji Sakuma; Shinji Matsunaga; Ikuo Nomura; Makoto Okuya; Taro Kishi; Nakao Iwata
Journal:  Psychopharmacology (Berl)       Date:  2018-05-22       Impact factor: 4.530

5.  Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).

Authors:  Eric D A Hermes; Daniel Sokoloff; T Scott Stroup; Robert A Rosenheck
Journal:  J Clin Psychiatry       Date:  2012-04       Impact factor: 4.384

6.  Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials.

Authors:  Taro Kishi; Kazuto Oya; Yuki Matsui; Ikuo Nomura; Kenji Sakuma; Makoto Okuya; Yuki Matsuda; Kiyoshi Fujita; Toshihiko Funahashi; Reiji Yoshimura; Nakao Iwata
Journal:  Neuropsychiatr Dis Treat       Date:  2018-10-01       Impact factor: 2.570

7.  Efficacy and Safety of Low-Dose Brexpiprazole for Acute Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials.

Authors:  Mingjun Zhao; Bin Qin; Yage Mao; Hailing Wang; Aiqin Wang; Chuansheng Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2022-08-11       Impact factor: 2.989

8.  Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia.

Authors:  Eleni Jelastopulu; Evangelia Giourou; Giorgos Merekoulias; Angeliki Mestousi; Eleftherios Moratis; Evangelos C Alexopoulos
Journal:  BMC Psychiatry       Date:  2014-07-08       Impact factor: 3.630

9.  Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis.

Authors:  Taro Kishi; Toshikazu Ikuta; Kazuto Oya; Shinji Matsunaga; Yuki Matsuda; Nakao Iwata
Journal:  Int J Neuropsychopharmacol       Date:  2018-08-01       Impact factor: 5.176
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.